May 13, 2021
Business News

Polyneuron and University of Basel Awarded Grant of CHF 1.2M to Advance Novel Treatments to Support ABO-Incompatible Transplants

BASEL, Switzerland–()–Polyneuron Pharmaceuticals AG, a clinical-stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced that the company and collaborators at the University of Basel have received a grant from the Swiss Innovation Agency Innosuisse to support a project valued at CHF 1.2 million. The project will advance the development of novel injectable glycopolymers to support better ABO-incompatible (ABOi) transplantation patient outcomes. ABOi transplantation, a procedure to transplant solid organs and stem cells without matching ABO blood groups, has been introduced to decrease recipient waiting time and the strongly…

Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
GoodRx Releases First Quarter 2021 Financial Results
Hess Midstream LP to Participate in EIC Investor Conference
Dillard’s, Inc. Reports First Quarter Results